Open an account

Iterum Therapeutics

ITRMF · NASDAQ

$0.00+$0.00 (+0.00%)TodayMarket closed ·
No price history for this range.

About ITRMF

Iterum Therapeutics Plc operates as a pharmaceutical company, which engages in the development and commercialization of sulopenem. The company is headquartered in Dublin, Dublin and currently employs 9 full-time employees. The company went IPO on 2018-05-25. The firm develops differentiated anti-infectives. The company offers ORLYNVAH (oral sulopenem) medicine, which is an oral penem antibiotic for the treatment of uncomplicated urinary tract infections (uUTIs) caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women. Sulopenem is a potent, thiopenem antibiotic delivered intravenously which is active against bacteria that belongs to the group of organisms known as gram-negatives and cause urinary tract and intra-abdominal infections. The firm operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.

Employees
9
Headquarters
DUBLIN, Dublin
Listed
May 25, 2018
Sector
Health Care
Industry
Pharmaceuticals
Website
iterumtx.com

ITRMF key statistics

Market cap
53
Price-earnings ratio
-0.00
Dividend yield
—
Average volume
120.57K
Volume
1.74K
Open price
$0.00
High today
$0.00
Low today
$0.00
52 Week high
$0.081
52 Week low
$0.00

Iterum Therapeutics (ITRMF) at a glance

As of Sep 8, 2026, Iterum Therapeutics (ITRMF) shares are priced at $0.00, giving the company a market cap of 53 and a price-to-earnings ratio of 0.00.

Volume so far is 1.74K shares, below the average of 120.57K shares a day.

Over the past year Iterum Therapeutics has ranged from $0.00 to $0.081, and now sits 0% of the way up that range.

Iterum Therapeutics met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q3 FY25 it reported -$0.20 per share against an estimate of -$0.1133.

ITRMF earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 20.6% on average.

  1. Q4 FY23: reported -$0.94 per share against an estimate of -$0.9631
  2. Q1 FY24: reported -$0.46 per share against an estimate of -$0.7468
  3. Q2 FY24: reported -$0.30 per share against an estimate of -$0.4635
  4. Q3 FY24: reported -$0.30 per share against an estimate of -$0.206
  5. Q4 FY24: reported -$0.23 per share against an estimate of -$0.2215
  6. Q1 FY25: reported -$0.14 per share against an estimate of -$0.1493
  7. Q2 FY25: reported -$0.16 per share against an estimate of -$0.1133
  8. Q3 FY25: reported -$0.20 per share against an estimate of -$0.1133

Similar companies

Companies in the same industry as Iterum Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.